₹88.0
+0.4% today
· 30d +1.38%
as of 2026-09-04
Price · Daily Candles
AI narrative is temporarily unavailable for BALPHARMA. The deterministic sections below render from live data.
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹89 Cr
+34.53% YoY
NET PROFIT
₹1 Cr
+445.66% YoY
OPM
9.42%
-0.77pp YoY
EPS
₹0.71
PE 20.46
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-50.0%, h2=-50.0%, h3=-50.0% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
ML Forward Growth Predictions 🔒
59
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
POSITIVE
55
Valuation
REASONABLE
60
Growth
MUTED
37
Profitability
DECENT
58
Technicals
NEUTRAL
55
Risk
LOW
90
Key Stats
TTM PE
20.46
P/B
1.79
52W HIGH
₹98.85
OFF HIGH
-10.98%
DIV YIELD
1.37%
MKT CAP
₹140 Cr
◉ Active Signals
MACDNeutral0.1622
RSI(14)Neutral54.89
⧉ Strategy Fit 🔒